Research outputs
2025
Eating traits and behaviours: How do people with Type 2 Diabetes compare to those without? A Scoping Review
Paniagua, R., Bradshaw, D., Bresnahan, R., Maden, M., Mangal, M., & Boyland, E. (2025). Eating traits and behaviours: How do people with Type 2 Diabetes compare to those without? A Scoping Review. Appetite, 213, 108110. doi:10.1016/j.appet.2025.108110
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]: A Single Technology Appraisal
Bresnahan, R., Harvey, R., Stainthorpe, A., Bryning, S., Beale, S., Boland, A., . . . Malik, Z. (2025). Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]: A Single Technology Appraisal. Retrieved from https://www.nice.org.uk/guidance/ta1086/documents/committee-papers-2
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]: A Single Technology Appraisal
Fleeman, N., Stainthorpe, A., Beale, S., Boland, A., Chaplin, M., Bresnahan, R., . . . Campbell, L. (2025). Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]: A Single Technology Appraisal. Retrieved from https://www.nice.org.uk/guidance/ta1042/documents/committee-papers
Biopsychosocial Approaches for the Management of Female Chronic Pelvic Pain: A Systematic Review
Johnson, S., Bradshaw, A., Bresnahan, R., Evans, E., Herron, K., & Hapangama, D. K. (2025). Biopsychosocial Approaches for the Management of Female Chronic Pelvic Pain: A Systematic Review. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 132(3), 266-277. doi:10.1111/1471-0528.17987
O035 REPORTING GUIDELINES FOR CLINICAL TRIAL PROTOCOLS AND REPORTS OF IMPLANTABLE NEUROSTIMULATION DEVICES: SPIRIT-INEUROSTIM AND CONSORT-INEUROSTIM EXTENSIONS
Eldabe, S., Bresnahan, R., Copley, S., North, R., Thomson, S., Baranidharan, G., . . . Duarte, R. (2025). O035 REPORTING GUIDELINES FOR CLINICAL TRIAL PROTOCOLS AND REPORTS OF IMPLANTABLE NEUROSTIMULATION DEVICES: SPIRIT-INEUROSTIM AND CONSORT-INEUROSTIM EXTENSIONS. Neuromodulation: Technology at the Neural Interface, 28(1), S76. doi:10.1016/j.neurom.2024.09.136
2024
Reporting guidelines for protocols of randomised controlled trials of implantable neurostimulation devices: the SPIRIT-iNeurostim extension
Bresnahan, R., Copley, S., Eldabe, S., Thomson, S., North, R. B., Baranidharan, G., . . . Duarte, R. V. (2024). Reporting guidelines for protocols of randomised controlled trials of implantable neurostimulation devices: the SPIRIT-iNeurostim extension. ECLINICALMEDICINE, 78. doi:10.1016/j.eclinm.2024.102933
Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORTiNeurostim extension
V. Duarte, R., Bresnahan, R., Copley, S., Eldabe, S., Thomson, S., North, R. B., . . . Taylor, R. S. (2024). Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORTiNeurostim extension. ECLINICALMEDICINE, 78. doi:10.1016/j.eclinm.2024.102932
Estimated health effects from domestic use of gaseous fuels for cooking and heating in high-income, middle-income, and low-income countries: a systematic review and meta-analyses
Puzzolo, E., Fleeman, N., Lorenzetti, F., Rubinstein, F., Li, Y., Xing, R., . . . Pope, D. (2024). Estimated health effects from domestic use of gaseous fuels for cooking and heating in high-income, middle-income, and low-income countries: a systematic review and meta-analyses. LANCET RESPIRATORY MEDICINE, 12(4), 281-293. doi:10.1016/S2213-2600(23)00427-7
Talazoparib for HER2-negative locally advanced or metastatic breast cancer with germline BRCA1/2-mutations [ID1342]: A Single Technology Appraisal
Fleeman, N., Bresnahan, R., Mahon, J., Chaplin, M., Beale, S., Boland, A., . . . Palmieri, C. (2024). Talazoparib for HER2-negative locally advanced or metastatic breast cancer with germline BRCA1/2-mutations [ID1342]: A Single Technology Appraisal. Retrieved from https://www.nice.org.uk/
Nivolumab-relatlimab for untreated unresectable or metastatic melanoma [ID1688]: A Single Technology Appraisal.
Bresnahan, R., Fleeman, N., Stainthorpe, A., Bryning, S., Nevitt, S., Mahon, J., . . . Danson, S. (2024). Nivolumab-relatlimab for untreated unresectable or metastatic melanoma [ID1688]: A Single Technology Appraisal.. Retrieved from https://www.nice.org.uk/guidance/ta950/documents/committee-papers
2023
Lamotrigine add-on therapy for drug-resistant focal epilepsy
Panebianco, M., Bresnahan, R., & Marson, A. G. (2023). Lamotrigine add-on therapy for drug-resistant focal epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (12). doi:10.1002/14651858.CD001909.pub4
Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15 (vol 7, pg 863, 2023)
Chaplin, M., Bresnahan, R., Fleeman, N., Mahon, J., Houten, R., Beale, S., . . . Munot, P. (2023). Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15 (vol 7, pg 863, 2023). PHARMACOECONOMICS-OPEN, 7(6), 1015. doi:10.1007/s41669-023-00462-7
Momelotinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis [ID6141]: A Single Technology Appraisal
Fleeman, N., Bresnahan, R., Mahon, J., Bryning, S., Beale, S., Boland, A., . . . Butt, N. (2023). Momelotinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis [ID6141]: A Single Technology Appraisal. Retrieved from https://www.nice.org.uk/guidance/ta957/evidence/committee-papers-pdf-13363268509
Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15
Chaplin, M., Bresnahan, R., Fleeman, N., Mahon, J., Houten, R., Beale, S., . . . Munot, P. (2023). Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15. PharmacoEconomics - Open. doi:10.1007/s41669-023-00439-6
Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bresnahan, R., Houten, R., Greenhalgh, J., Nevitt, S., Mahon, J., Beale, S., . . . Chaplin, M. (2023). Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.. PharmacoEconomics - open. doi:10.1007/s41669-023-00408-z
Perampanel add-on for drug-resistant focal epilepsy.
Bresnahan, R., Hill, R. A., & Wang, J. (2023). Perampanel add-on for drug-resistant focal epilepsy.. The Cochrane database of systematic reviews, 4, CD010961. doi:10.1002/14651858.cd010961.pub2
Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non- alcoholic fatty liver disease: systematic review and economic evaluation
Bresnahan, R., Duarte, R., Mahon, J., Beale, S., Chaplin, M., Bhattacharyya, D., . . . Boland, A. (2023). Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non- alcoholic fatty liver disease: systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 27(10). doi:10.3310/KGJU3398
2022
Health effects of liquid and gaseous fuels for household energy use: systematic evidence mapping
Nix, E., Fleeman, N., Lorenzetti, F., Lewis, J., Shen, G., Abebe, L., . . . Puzzolo, E. (2022). Health effects of liquid and gaseous fuels for household energy use: systematic evidence mapping. ENVIRONMENTAL RESEARCH LETTERS, 17(12). doi:10.1088/1748-9326/aca1d2
Onasemnogene abeparvovec for treating pre-symptomatic spinal muscular atrophy (MAA partial review of HST 15) [ID4051]: A Highly Specialised Technology appraisal
Bresnahan, R., Fleeman, N., Mahon, J., Houten, R., Chaplin, M., Beale, S., . . . Munot, P. (2022). Onasemnogene abeparvovec for treating pre-symptomatic spinal muscular atrophy (MAA partial review of HST 15) [ID4051]: A Highly Specialised Technology appraisal. Retrieved from https://www.nice.org.uk/guidance/hst24/history
Felbamate add-on therapy for drug-resistant focal epilepsy
Shi, L. L., Bresnahan, R., Martin-McGill, K. J., Dong, J., Ni, H., & Geng, J. (2022). Felbamate add-on therapy for drug-resistant focal epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (8). doi:10.1002/14651858.CD008295.pub6
Pregabalin add-on for drug-resistant focal epilepsy
Panebianco, M., Bresnahan, R., & Marson, A. G. (2022). Pregabalin add-on for drug-resistant focal epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (3). doi:10.1002/14651858.CD005612.pub5
Brivaracetam add-on therapy for drug-resistant epilepsy
Bresnahan, R., Panebianco, M., & Marson, A. G. (2022). Brivaracetam add-on therapy for drug-resistant epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (3). doi:10.1002/14651858.CD011501.pub3
2021
Reporting Guidelines for Clinical Trial Protocols and Reports of Implantable Neurostimulation Devices: Protocol for the SPIRIT-iNeurostim and CONSORT-iNeurostim Extensions.
Duarte, R. V., Bresnahan, R., Copley, S., Eldabe, S., Thomson, S., North, R. B., . . . SPIRIT-iNeurostim and CONSORT-iNeurostim Working Group. (2021). Reporting Guidelines for Clinical Trial Protocols and Reports of Implantable Neurostimulation Devices: Protocol for the SPIRIT-iNeurostim and CONSORT-iNeurostim Extensions.. Neuromodulation : journal of the International Neuromodulation Society. doi:10.1016/j.neurom.2021.10.006
Carisbamate add-on therapy for drug-resistant focal epilepsy
Lu, C., Zheng, J., Cao, Y., Bresnahan, R., & Martin-McGill, K. J. (2021). Carisbamate add-on therapy for drug-resistant focal epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (12). doi:10.1002/14651858.CD012121.pub2
Cochrane systematic review and meta-analysis of the impact of psychological treatment on health-related quality of life in people with epilepsy: an update by the ILAE Psychology Task Force, highlighting methodological changes
Michaelis, R., Tang, V., Nevitt, S. J., Wagner, J. L., Modi, A. C., LaFrance, W. C. J., . . . Reuber, M. (2021). Cochrane systematic review and meta-analysis of the impact of psychological treatment on health-related quality of life in people with epilepsy: an update by the ILAE Psychology Task Force, highlighting methodological changes. EPILEPTIC DISORDERS, 23(6), 803-811. doi:10.1684/epd.2021.1357
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria [ID3746]
Bresnahan, R., Houten, R., Mahon, J., Beale, S., Nevitt, S., Greenhalgh, J., . . . Gandhi, S. (2021). Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria [ID3746]: Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria [ID3746]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/rebecca-bresnahan/
Valproate add‐on therapy for drug‐resistant focal epilepsy
Gianatsi, M., Bresnahan, R., Hill, R. A., Nevitt, S. J., Marson, A. G., & Tudur Smith, C. (2021). Valproate add‐on therapy for drug‐resistant focal epilepsy. The Cochrane database of systematic reviews, 2021(7).
Lacosamide add-on therapy for focal epilepsy
Babar, R. K., Bresnahan, R., Gillespie, C. S., & Michael, B. D. (2021). Lacosamide add-on therapy for focal epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (5). doi:10.1002/14651858.CD008841.pub3
Nivolumab in combination with chemotherapy for untreated advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma [ID1465]
Greenhalgh, J., Mahon, J., Nevitt, S., Bresnahan, R., Boland, A., Beale, S., . . . Boon, C. (2021). Nivolumab in combination with chemotherapy for untreated advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma [ID1465]: Nivolumab in combination with chemotherapy for untreated advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma [ID1465]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/
2020
Selpercatinib for RET fusion-positive advanced non-small-cell lung cancer [ID3743]
Bresnahan, R., Mahon, J., Nevitt, S., Beale, S., Boland, A., Greenhalgh, J., . . . Campbell, L. (2020). Selpercatinib for RET fusion-positive advanced non-small-cell lung cancer [ID3743]: Selpercatinib for RET fusion-positive advanced non-small-cell lung cancer [ID3743]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/rebecca-bresnahan/
Sapropterin dihydrochloride for treating phenylketonuria [ID1475]
Greenhalgh, J., James, M., Nevitt, S., Bresnahan, R., Beale, S., Boland, A., . . . Schwan, B. (2020). Sapropterin dihydrochloride for treating phenylketonuria [ID1475]: Sapropterin dihydrochloride for treating phenylketonuria [ID1475]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/
Psychological treatments for people with epilepsy
Michaelis, R., Tang, V., Nevitt, S. J., Wagner, J. L., Modi, A. C., LaFrance, W. C. J., . . . Reuber, M. (2020). Psychological treatments for people with epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (9). doi:10.1002/14651858.CD012081.pub3
Vigabatrin add-on therapy for drug-resistant focal epilepsy
Bresnahan, R., Gianatsi, M., Maguire, M. J., Tudur Smith, C., & Marson, A. G. (2020). Vigabatrin add-on therapy for drug-resistant focal epilepsy. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd007302.pub3
Brigatinib for ALK-positive advanced non-small cell lung cancer that has not been previously treated with an ALK inhibitor [ID1468]
Greenhalgh, J., Lambe, T., Mahon, J., Nevitt, S., Edwards, K., Bresnahan, R., . . . Green, J. (2020). Brigatinib for ALK-positive advanced non-small cell lung cancer that has not been previously treated with an ALK inhibitor [ID1468]: Brigatinib for ALK-positive advanced non-small cell lung cancer that has not been previously treated with an ALK inhibitor [ID1468]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/
Lamotrigine add-on therapy for drug-resistant generalised tonic-clonic seizures
Bresnahan, R., Panebianco, M., & Marson, A. G. (2020). Lamotrigine add-on therapy for drug-resistant generalised tonic-clonic seizures. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (7). doi:10.1002/14551858.00007783.pub3
Ketogenic diets for drug-resistant epilepsy
Martin-McGill, K. J., Bresnahan, R., Levy, R. G., & Cooper, P. N. (2020). Ketogenic diets for drug-resistant epilepsy. Cochrane Database of Systematic Reviews, (6). doi:10.1002/14651858.CD001903.pub5
Midostaurin for treating advanced systemic mastocytosis [ID1573]
Greenhalgh, J., Lambe, T., Nevitt, S., Mahon, J., Boland, A., Beale, S., . . . Moonim, M. (2020). Midostaurin for treating advanced systemic mastocytosis [ID1573]: Midostaurin for treating advanced systemic mastocytosis [ID1573]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/
Lamotrigine add-on therapy for drug-resistant focal epilepsy.
Panebianco, M., Bresnahan, R., Ramaratnam, S., & Marson, A. G. (2020). Lamotrigine add-on therapy for drug-resistant focal epilepsy.. The Cochrane database of systematic reviews, 3. doi:10.1002/14651858.cd001909.pub3
Oxcarbazepine add-on for drug-resistant focal epilepsy
Bresnahan, R., Atim-Oluk, M., & Marson, A. G. (2020). Oxcarbazepine add-on for drug-resistant focal epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (3). doi:10.1002/14651858.CD012433.pub2
2019
Topiramate add-on therapy for drug-resistant focal epilepsy
Bresnahan, R., Hounsome, J., Jette, N., Hutton, J. L., & Marson, A. G. (2019). Topiramate add-on therapy for drug-resistant focal epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (10). doi:10.1002/14651858.CD001417.pub4
Clobazam add-on therapy for drug-resistant epilepsy
Bresnahan, R., Martin-McGill, K. J., Williamson, J., Michael, B. D., & Marson, A. G. (2019). Clobazam add-on therapy for drug-resistant epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (10). doi:10.1002/14651858.CD004154.pub5
Tiagabine add-on therapy for drug-resistant focal epilepsy
Bresnahan, R., Martin-McGill, K. J., Hutton, J. L., & Marson, A. G. (2019). Tiagabine add-on therapy for drug-resistant focal epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (10). doi:10.1002/14651858.CD001908.pub4
Developing resources to support shared decision making for add-on therapies in drug-resistant epilepsy
Bresnahan, R., Panebianco, M., Hill, R. A., Pullen, A., Haydon, G., & Marson, A. (2019). Developing resources to support shared decision making for add-on therapies in drug-resistant epilepsy. Poster session presented at the meeting of International League Against Epilepsy British Branch Annual Scientific Meeting. Birmingham.
Sulthiame add-on therapy for epilepsy
Bresnahan, R., Martin-McGill, K. J., Milburn-McNulty, P., Powell, G., Sills, G. J., & Marson, A. G. (2019). Sulthiame add-on therapy for epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (8). doi:10.1002/14651858.CD009472.pub4
Felbamate add-on therapy for drug-resistant focal epilepsy
Shi, L. L., Bresnahan, R., Martin-McGill, K. J., Dong, J., Ni, H., & Geng, J. (2019). Felbamate add-on therapy for drug-resistant focal epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (8). doi:10.1002/14651858.CD008295.pub5
Pregabalin add-on for drug-resistant focal epilepsy
Panebianco, M., Bresnahan, R., Hemming, K., & Marson, A. G. (2019). Pregabalin add-on for drug-resistant focal epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (7). doi:10.1002/14651858.CD005612.pub4
Brivaracetam add-on therapy for drug-resistant epilepsy
Bresnahan, R., Panebianco, M., & Marson, A. G. (2019). Brivaracetam add-on therapy for drug-resistant epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (3). doi:10.1002/14651858.CD011501.pub2
2018
Ketogenic diets for drug-resistant epilepsy
Martin-McGill, K. J., Jackson, C. F., Bresnahan, R., Levy, R. G., & Cooper, P. N. (2018). Ketogenic diets for drug-resistant epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (11). doi:10.1002/14651858.CD001903.pub4
2016
Motor Cortex Reorganization and Repetitive Transcranial Magnetic Stimulation for Pain-A Methodological Study
Nurmikko, T., MacIver, K., Bresnahan, R., Hird, E., Nelson, A., & Sacco, P. (2016). Motor Cortex Reorganization and Repetitive Transcranial Magnetic Stimulation for Pain-A Methodological Study. NEUROMODULATION, 19(7), 669-678. doi:10.1111/ner.12444
2014
Somatosensory Change and Pain Relief Induced by Repetitive Transcranial Magnetic Stimulation in Patients With Central Poststroke Pain
Hasan, M., Whiteley, J., Bresnahan, R., MacIver, K., Sacco, P., Das, K., & Nurmikko, T. (2014). Somatosensory Change and Pain Relief Induced by Repetitive Transcranial Magnetic Stimulation in Patients With Central Poststroke Pain. NEUROMODULATION, 17(8), 731-736. doi:10.1111/ner.12198
Undated
Health Effects from Domestic Use of Gaseous and Liquid Fuels for Cooking and Heating in High, Middle and Low-Income Countries: A Systematic Review and Meta-Analysis
Puzzolo, E., Fleeman, N., Lorenzetti, F., Rubinstein, F., Li, Y., Xing, R., . . . Pope, D. (n.d.). Health Effects from Domestic Use of Gaseous and Liquid Fuels for Cooking and Heating in High, Middle and Low-Income Countries: A Systematic Review and Meta-Analysis.